BR112014008552A2 - r(+)-n-metil-propargilaminoindano - Google Patents
r(+)-n-metil-propargilaminoindanoInfo
- Publication number
- BR112014008552A2 BR112014008552A2 BR112014008552A BR112014008552A BR112014008552A2 BR 112014008552 A2 BR112014008552 A2 BR 112014008552A2 BR 112014008552 A BR112014008552 A BR 112014008552A BR 112014008552 A BR112014008552 A BR 112014008552A BR 112014008552 A2 BR112014008552 A2 BR 112014008552A2
- Authority
- BR
- Brazil
- Prior art keywords
- methylpropargylaminoindane
- salt
- aminoindane
- validating
- rasagiline
- Prior art date
Links
- CSVGVHNFFZWQJU-UHFFFAOYSA-N n-methyl-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N(CC#C)C)CCC2=C1 CSVGVHNFFZWQJU-UHFFFAOYSA-N 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 abstract 2
- 229960000245 rasagiline Drugs 0.000 abstract 2
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- SQGPJNRKLZOTMK-UHFFFAOYSA-N n-methyl-1-prop-2-ynyl-2,3-dihydroinden-1-amine Chemical compound C1=CC=C2C(NC)(CC#C)CCC2=C1 SQGPJNRKLZOTMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545426P | 2011-10-10 | 2011-10-10 | |
| PCT/US2012/059358 WO2013055689A1 (en) | 2011-10-10 | 2012-10-09 | R(+)-n-methyl-propargyl-aminoindan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014008552A2 true BR112014008552A2 (pt) | 2017-04-18 |
Family
ID=48042233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014008552A BR112014008552A2 (pt) | 2011-10-10 | 2012-10-09 | r(+)-n-metil-propargilaminoindano |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9339469B2 (enExample) |
| EP (1) | EP2766004A4 (enExample) |
| JP (1) | JP2014534197A (enExample) |
| KR (1) | KR20140084153A (enExample) |
| CN (1) | CN103930100A (enExample) |
| AR (1) | AR088766A1 (enExample) |
| AU (1) | AU2012323351A1 (enExample) |
| BR (1) | BR112014008552A2 (enExample) |
| CA (1) | CA2851433A1 (enExample) |
| EA (1) | EA201490760A1 (enExample) |
| HK (1) | HK1200314A1 (enExample) |
| IL (1) | IL231722A0 (enExample) |
| MX (1) | MX2014004201A (enExample) |
| WO (1) | WO2013055689A1 (enExample) |
| ZA (1) | ZA201403050B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EA016820B1 (ru) * | 2006-12-14 | 2012-07-30 | Тева Фармасьютикал Индастриз, Лтд. | Кристаллическое твердое основание разагилина |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| ES2389353T3 (es) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
| RS53504B1 (sr) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | Soli razagilina i njihovi farmaceutski preparati |
| US20110130466A1 (en) * | 2009-10-09 | 2011-06-02 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2939669A1 (en) * | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| KR20140090996A (ko) | 2011-10-10 | 2014-07-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | R(+)-n-폼일-프로파길-아미노인단 |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
| ITUB20160650A1 (it) * | 2016-02-11 | 2017-08-11 | Dipharma S A | Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione |
| CN111983075A (zh) * | 2020-08-17 | 2020-11-24 | 重庆华森制药股份有限公司 | 一种检测雷沙吉兰及其对映异构体的方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69732984T2 (de) | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| EP2526944B1 (en) | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| EP1778196A4 (en) | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| CN101098685A (zh) | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| KR20140103356A (ko) | 2005-02-23 | 2014-08-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 함량 균일성이 개선된 라사길린 제형 |
| EP1954667B1 (en) | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| EP1991214B1 (en) | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| WO2008076315A1 (en) | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| EA016820B1 (ru) | 2006-12-14 | 2012-07-30 | Тева Фармасьютикал Индастриз, Лтд. | Кристаллическое твердое основание разагилина |
| EP1987816A1 (de) | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| EP2194780A4 (en) | 2007-09-05 | 2010-10-27 | Teva Pharma | METHOD FOR TREATING GLAUCOMA BY RASAGILINE |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| ES2389353T3 (es) | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
| JP2011522892A (ja) | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | パーキンソン病緩和のためのラサギリン |
| CA2727021A1 (en) | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| WO2009154777A2 (en) | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| RS53504B1 (sr) | 2009-07-09 | 2015-02-27 | Ratiopharm Gmbh | Soli razagilina i njihovi farmaceutski preparati |
| US20110130466A1 (en) | 2009-10-09 | 2011-06-02 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2939669A1 (en) | 2009-12-22 | 2015-11-04 | Teva Pharmaceutical Industries, Ltd. | 3-keto-n-propargyl-1-aminoindan |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| AU2011282720B2 (en) | 2010-07-27 | 2016-12-22 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| EA201390613A1 (ru) | 2010-10-26 | 2013-11-29 | Тева Фармасьютикал Индастриз Лтд. | Обогащенный дейтерием расагилин |
| US20130089611A1 (en) | 2011-10-10 | 2013-04-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline citramide |
| KR20140090996A (ko) | 2011-10-10 | 2014-07-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | R(+)-n-폼일-프로파길-아미노인단 |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
-
2012
- 2012-10-09 AU AU2012323351A patent/AU2012323351A1/en not_active Abandoned
- 2012-10-09 CA CA2851433A patent/CA2851433A1/en not_active Abandoned
- 2012-10-09 CN CN201280054932.3A patent/CN103930100A/zh active Pending
- 2012-10-09 BR BR112014008552A patent/BR112014008552A2/pt not_active IP Right Cessation
- 2012-10-09 EP EP12840761.6A patent/EP2766004A4/en not_active Withdrawn
- 2012-10-09 EA EA201490760A patent/EA201490760A1/ru unknown
- 2012-10-09 JP JP2014535790A patent/JP2014534197A/ja active Pending
- 2012-10-09 KR KR1020147012455A patent/KR20140084153A/ko not_active Withdrawn
- 2012-10-09 US US13/647,622 patent/US9339469B2/en not_active Expired - Fee Related
- 2012-10-09 WO PCT/US2012/059358 patent/WO2013055689A1/en not_active Ceased
- 2012-10-09 HK HK15100234.9A patent/HK1200314A1/xx unknown
- 2012-10-09 MX MX2014004201A patent/MX2014004201A/es not_active Application Discontinuation
- 2012-10-10 AR ARP120103782A patent/AR088766A1/es unknown
-
2014
- 2014-03-26 IL IL231722A patent/IL231722A0/en unknown
- 2014-04-25 ZA ZA2014/03050A patent/ZA201403050B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013055689A1 (en) | 2013-04-18 |
| EP2766004A4 (en) | 2015-04-22 |
| IL231722A0 (en) | 2014-05-28 |
| JP2014534197A (ja) | 2014-12-18 |
| HK1200314A1 (en) | 2015-08-07 |
| EP2766004A1 (en) | 2014-08-20 |
| AR088766A1 (es) | 2014-07-02 |
| CN103930100A (zh) | 2014-07-16 |
| MX2014004201A (es) | 2015-01-12 |
| CA2851433A1 (en) | 2013-04-18 |
| ZA201403050B (en) | 2015-08-26 |
| US9339469B2 (en) | 2016-05-17 |
| EA201490760A1 (ru) | 2014-09-30 |
| KR20140084153A (ko) | 2014-07-04 |
| WO2013055689A8 (en) | 2014-04-10 |
| AU2012323351A1 (en) | 2014-05-22 |
| US20130089610A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014008552A2 (pt) | r(+)-n-metil-propargilaminoindano | |
| CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| BR112015005048A8 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
| BR112015014372A2 (pt) | inibidores de autotaxina | |
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| BR112013002484A2 (pt) | composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto. | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| BR112014008550A2 (pt) | citramida rasagilina | |
| MY166045A (en) | Abeta antibody formulation | |
| EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| MX2016015006A (es) | Formulacion de anticuerpos. | |
| EA201301240A1 (ru) | Полиморфная форма бензоата линаглиптина | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| PH12014501991B1 (en) | Phenicol antibacterials | |
| NI201500096A (es) | Compuesto químicos | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| BR112017001860A2 (pt) | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |